Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    thumbnails
    Download 2025 Global and China biotech sector survey reports

    Two new reports of surveys of 260+ Global and China biotech leaders have just been released

    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    thumbnail
    ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change

    Watch the webinar.

    data network
    Riding the data wave: How pharma can navigate disruptions in open claims

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Showing 685 - 696 of 955 results for "*"

ICON Plc facebook post
ICON Plc logo
ICON Plc

We’re looking forward to joining the conversation at #OCTNewEngland. On October 15 at 11:30 AM, our General Partner and VP of Operations, Stacey Flattery, will speak on: “Maneuvering with agility in a challenging landsc...

14 Oct
3
Social media image
ICON Plc logo
ICON Plc

We’re looking forward to joining the conversation at #OCTNewEngland. On October 15 at 11:30 AM, our General Partner and VP of Operations, Stacey Flattery, will speak on: “Maneuvering with agility in a challenging landsc...

14 Oct
ICON Plc facebook post
ICON Plc logo
ICON Plc

From molecule to market - see how ICON supports oncology sponsors with tailored strategies, from logistics to regulatory, across every phase. Explore oncology case studies: https://ow.ly/2Xqk50WY1mg

14 Oct
1
Social media image
ICON Plc logo
ICON Plc

From molecule to market - see how ICON supports oncology sponsors with tailored strategies, from logistics to regulatory, across every phase. Explore oncology case studies: https://ow.ly/Jjhf50WY1mh

14 Oct
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON is pleased to invite you to an upcoming webinar titled “Introducing ICON strategic solutions FSP services: How this model supports sponsors in Korea,” taking place on 28 October at 2:00 PM KST. This session will pro...

14 Oct
1
Social media image
ICON Plc logo
ICON Plc

ICON is pleased to invite you to an upcoming webinar titled “Introducing ICON strategic solutions FSP services: How this model supports sponsors in Korea,” taking place on 28 October at 2:00 PM KST. This session will pro...

14 Oct
Social media image
ICON Plc logo
ICON Plc

ICON’s Mia Carter joins a panel on Investigational Drug Accountability Management to discuss the real-world friction between clinical sites and sponsors and how to overcome it. Topics include regulatory alignment, effici...

13 Oct
ICON Plc facebook post
ICON Plc logo
ICON Plc

Why do stability studies matter in early drug development? From shelf-life determination to regulatory readiness, a well-designed stability program ensures your drug product remains safe, effective, and reliable. Learn...

13 Oct
1
Social media image
ICON Plc logo
ICON Plc

Why do stability studies matter in early drug development? From shelf-life determination to regulatory readiness, a well-designed stability program ensures your drug product remains safe, effective, and reliable. Learn...

13 Oct
Social media image
ICON Plc logo
ICON Plc

ICON will participate in the upcoming Medical Technology Enterprise Consortium (MTEC) webinar on 15 October from 1:00 pm to 2:00 pm. Timothy Bradshaw, Ph.D. and Edward Wright will speak on the topic: "Advancing ICON ea...

13 Oct
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON will participate in the upcoming Medical Technology Enterprise Consortium (MTEC) webinar on 15 October from 1:00 pm to 2:00 pm. Tim Bradshaw and Edward Wright will speak on the topic: "Advancing ICON early-stage c...

13 Oct
1
Social media image
ICON Plc logo
ICON Plc

Connect with the ICON team during ACR Convergence 2025 at booth \#1501, to discover how Accellacare—our Global Site Network with deep expertise in osteoarthritis, osteoporosis, and rheumatoid arthritis—supports sponsors ...

13 Oct
  • Previous
  • 1
  • …
  • 57
  • 58
  • 59
  • …
  • 80
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence